If your child has been diagnosed with myopia, you are facing more than just blurry vision. Myopia is a progressive eye condition that causes the eyeball to elongate over time. This creates higher risks of sight-threatening conditions throughout your child's life. Treatments now exist to slow this progression, and the FDA has authorized specific devices designed for pediatric myopia control.
The FDA's involvement in myopia control represents a major shift in how we approach childhood nearsightedness. For decades, standard single-vision glasses and contact lenses were the only options. These simply correct blurry vision without addressing the underlying disease process.
Recent FDA authorizations recognize that myopia is a progressive condition requiring intervention beyond basic vision correction. FDA-authorized myopia control treatments have undergone rigorous clinical trials demonstrating both safety and efficacy specifically for slowing myopia progression in children.
FDA-authorized treatments are not off-label uses or experimental approaches. They are treatments with robust clinical evidence showing measurable reductions in both refractive progression and axial elongation. Axial elongation is the physical lengthening of the eyeball that drives all the serious risks associated with myopia.
In September 2025, Stellest lenses received FDA authorization, representing a significant moment in myopia management. These are the first FDA-authorized eyeglass lenses specifically designed to help slow myopia progression in children. This authorization followed rigorous U.S. clinical trials demonstrating safety and efficacy in children aged 6 to 12 years.
Stellest lenses look like regular glasses, but they incorporate optical technology called H.A.L.T., which stands for Highly Aspherical Lenslet Target. The lens features a clear central zone that provides normal, sharp vision, surrounded by 1,021 tiny aspherical lenslets arranged in 11 concentric rings. These microscopic lenslets create a controlled volume of light in front of the retina, sending a biological signal to the eye to slow its elongation.
The evidence supporting FDA authorization is strong. Over two years, children wearing Stellest lenses showed 71% less refractive progression and 53% less axial elongation compared with children wearing standard single-vision lenses.
In practical terms, if a child would typically progress by 1.00 diopter per year without treatment, Stellest could reduce that to approximately 0.30 diopters per year. Over five years of childhood growth, that is the difference between accumulating 5.00 diopters versus 1.50 diopters. This difference could mean avoiding high myopia and significantly reducing lifetime risk of vision-threatening complications.
Stellest lenses are designed for children typically between ages 6 and 12 years with myopia ranging from approximately -0.75D to -4.50D, with up to about 1.50D of astigmatism. They are particularly well-suited for:
For best results, consistent daily wear of at least 10 hours per day, 6 days per week is recommended. Twelve or more hours daily may provide even better results. The lenses are made from impact-resistant polycarbonate material, making them safe for active play, school activities, and most sports.
MiSight 1 Day contact lenses were the first FDA-authorized contact lenses specifically designed to slow myopia progression in children. These soft, daily disposable lenses are designed for children who prefer the freedom from glasses during sports, social activities, and daily life.
The lenses feature a dual-focus optical design with treatment zones that create myopic defocus on the peripheral retina while providing clear central vision. Like Stellest, this optical design sends signals to the eye to slow its elongation. Children wear them during the day like regular contact lenses, then dispose of them each night. This eliminates any cleaning or maintenance routines.
Clinical trials supporting FDA authorization demonstrated that MiSight contact lenses show 59% reduction in refractive progression and 52% reduction in axial length growth over three years. These results are comparable to Stellest lenses, making both treatments highly effective options for pediatric myopia control.
The studies followed children aged 8 to 12 years old at enrollment, tracking their progression over multiple years. The consistent findings demonstrate that MiSight provides sustained myopia control benefits when worn consistently throughout childhood.
MiSight lenses are well-suited for:
The lenses require proper hygiene, including handwashing before insertion and removal, following wearing schedules, and disposing of lenses nightly. Children as young as 8 years old have successfully worn MiSight lenses in clinical trials. However, readiness depends more on maturity and responsibility level than age. Some 8-year-olds are ready, while some 12-year-olds may not be. Our optometrists evaluate each child individually to determine whether contact lens wear is appropriate.
While Stellest lenses and MiSight contact lenses have received specific FDA authorization for myopia control in children, other effective treatments exist that are used off-label. Off-label does not mean ineffective or unsafe. It simply means the FDA has not specifically authorized that particular use, though the treatment may be widely accepted and supported by extensive clinical research.
Orthokeratology involves wearing specially designed rigid contact lenses overnight to temporarily reshape the cornea. This allows clear vision during the day without any glasses or contacts. While the FDA has authorized certain orthokeratology lenses for overnight wear to correct myopia, the specific indication for slowing myopia progression in children is considered off-label use.
Despite the off-label designation, orthokeratology is supported by decades of research demonstrating 36% to 56% reduction in myopia progression depending on the specific study. The treatment offers complete daytime freedom from vision correction, which appeals to swimmers, athletes, and children who prefer not wearing anything on their eyes during the day.
Low-dose atropine therapy involves applying eye drops nightly at concentrations between 0.01% and 0.05%. Atropine is an anticholinergic medication that slows the biochemical signals causing the eyeball to elongate. While atropine has been FDA-authorized for other ophthalmic uses for nearly 100 years, its use for pediatric myopia control remains off-label.
Research suggests that low-dose atropine may provide 50% to 60% reduction in myopia progression, making it comparably effective to FDA-authorized optical treatments. The LAMP Study, a randomized, double-masked trial with 350 children ages 4 to 12, demonstrated efficacy at various low doses.
At ultra-low doses, side effects are minimal. Clinical trials found that approximately 23% to 24% of children experienced mild light sensitivity in bright sunlight during the first year. This was easily managed by wearing sunglasses. By the second year, no children reported any discomfort associated with the medication.
Neither Stellest nor MiSight is universally better than the other. Both are proven, FDA-authorized treatments that effectively slow myopia progression with comparable clinical outcomes. Stellest shows 71% reduction in progression while MiSight demonstrates 59% reduction. Both reduce axial elongation by approximately 52% to 53%.
The choice between these two excellent options depends primarily on lifestyle factors, personal preference, and maturity level. Consider:
Stellest offers the simplicity of eyeglasses without requiring daily contact lens insertion, removal, and hygiene routines. There is no worrying about whether your child washed their hands properly, no concern about eye infections from poor hygiene, and no running out of solution or supplies.
MiSight provides freedom from glasses that some children strongly prefer, especially for sports and social activities. Some children are self-conscious about wearing glasses or find them uncomfortable. MiSight gives these kids clear vision without anything on their face. However, it requires responsible contact lens handling, proper hygiene practices, and parental supervision, especially initially.
Research shows that slowing progression by just 1.00 diopter may reduce the risk of myopic maculopathy by approximately 40%. Slowing progression also helps reduce the risk of retinal detachment, cataracts, and glaucoma. Waiting is not neutral. Every year without treatment allows the eye to continue elongating, adding diopters that translate directly into lifetime disease risk. Our children's vision symptom checker can help you identify early warning signs.
Children with moderate myopia between -3.00D and -5.00D face significantly elevated risks compared to children with normal vision. These include approximately 9 times the risk of retinal detachment, 3 times the risk of cataracts, and 2 times the risk of glaucoma. High myopia (greater than -5.00D or -6.00D) creates even more concerning statistics, including substantially higher risk of myopic macular degeneration.
Early intervention during childhood, when progression is most rapid, is the most effective way to reduce the total amount of myopia your child develops. Myopia typically begins between ages 6 and 12 and progresses most rapidly during these years. Starting treatment as soon as myopia is detected helps maximize the benefit your child receives.
No FDA-authorized treatment works in isolation. Lifestyle modifications work together with optical or pharmacological interventions to support myopia control. The most important lifestyle factor is outdoor time. Research consistently shows that approximately 2 hours per day outdoors may provide protective benefits. Natural light triggers dopamine release in the retina, which helps slow eye elongation.
We recommend 90 to 120 minutes daily of outdoor activity. Think of outdoor time as part of the treatment plan, not just a suggestion.
Following the 20-20-20 rule helps reduce eye strain. Every 20 minutes, have your child look at something 20 feet away for at least 20 seconds. This gives the focusing muscles inside the eye a break from sustained near work. Maintaining appropriate reading distance and good lighting for near work also supports eye health.
The combination of FDA-authorized treatments plus healthy visual habits provides the best approach to myopia management. Neither works as well alone as they do together. Stellest or MiSight provides the foundation, while outdoor time and proper visual habits provide the supporting framework.
At Insight Vision Center Optometry, we offer all myopia management modalities: Stellest lenses, MiSight contact lenses, orthokeratology, and low-dose atropine. This allows us to provide truly individualized treatment recommendations based on your child's unique needs rather than being limited to a single approach.
Our optometrists include fellowship-trained doctors with credentials in myopia management. Dr. Thanh Mai, OD, FSLS serves as VP of Clinical Innovation for Treehouse Eyes and serves on the EssilorLuxottica advisory board for Stellest. Dr. Nathan Schramm, OD, FSLS, FBCLA has served as principal investigator on orthokeratology clinical trials. Dr. Ariel Chen, OD, Dr. Valerie Lam, OD, FAAO, FOVDR, and Dr. Nhi Nguyen, OD all bring additional training and experience in pediatric myopia management.
Our philosophy centers on customization over hierarchy. The best treatment depends on your child's unique circumstances, not on which option generates impressive statistics. We evaluate your child's eyes, discuss your family's lifestyle and preferences, and recommend the approach that makes the most sense for your situation.
Our practice uses the Zeiss AXL WAVE Optical Biometer and Pentacam for precise axial length measurement and corneal mapping. These tools help us establish baseline measurements and track your child's response to treatment over time.
The best way to determine which FDA-authorized or evidence-based treatment is right for your child is through a comprehensive myopia evaluation. This assessment includes a complete eye health examination, comprehensive refraction to determine the exact prescription, axial length measurement to establish baseline eye length for tracking, binocular vision assessment, risk factor evaluation examining family history and visual environment, and discussion of all treatment options with personalized recommendations.
This evaluation provides everything you need to make an informed decision about myopia management for your child. There is no pressure to commit immediately. Take time to discuss options as a family and prepare for beginning treatment when you are ready.
Call us at
(714) 486-3315 to schedule your child's myopia evaluation. You can also speak with our Myopia Management Care Coordinator for a phone consultation if you have questions before scheduling. Early intervention provides the greatest benefit. Myopia progression does not pause while you are deciding what to do.
Yes. Stellest lenses are made from impact-resistant polycarbonate material, making them safe for active play, school activities, and most sports. For contact sports where glasses might get knocked off, you may want to consider sports goggles or discuss MiSight contact lenses as an alternative option during athletic activities.
Missing an occasional day is not a major concern. However, consistent wear is important for best results. The clinical trials that demonstrated the effectiveness of these treatments were based on regular, daily use. Try to establish a routine so your child wears their Stellest lenses or MiSight contacts consistently each day.
Yes, in some cases combination therapy may be appropriate. For example, some children use both low-dose atropine drops and an optical treatment like Stellest or MiSight. Your eye doctor will discuss whether combination therapy makes sense for your child based on their progression rate, age, and other factors.
Most children continue myopia control treatment throughout their growing years, typically until their late teens when myopia progression naturally slows. Stopping treatment too early may allow progression to resume. Your eye doctor will monitor your child's eyes regularly and discuss the appropriate time to transition out of active myopia control.
Most children with progressive myopia are candidates for myopia control treatment. However, certain eye conditions or very high prescriptions may require different approaches. Children who cannot reliably care for contact lenses may be better suited for Stellest glasses. Your eye doctor will evaluate your child individually to determine the most appropriate treatment.
Most children on myopia control treatment are seen every 6 months. These visits include measuring prescription changes and axial length to track how well the treatment is working. More frequent visits may be needed initially when starting contact lenses or if your eye doctor wants to monitor progression more closely.
